A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer

This publication has 13 references indexed in Scilit:

• Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
  Breast Cancer Research and Treatment, 1999
• Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
  Cancer, 1998
• Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications
  The Journal of Steroid Biochemistry and Molecular Biology, 1998
• Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
  Journal of Surgical Oncology, 1997
• Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
  British Journal of Cancer, 1996
• The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitor
  The Journal of Steroid Biochemistry and Molecular Biology, 1996
• Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers
  British Journal of Cancer, 1996
• Arimidex : A potent and selective fourth-generation aromatase inhibitor
  Breast Cancer Research and Treatment, 1994
• 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer
  European Journal Of Cancer, 1992
• The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
  European Journal Of Cancer, 1992